ReviewFrontiers in immunology2026
Radiotherapy for overcoming immune checkpoint inhibitor resistance in esophageal squamous cell carcinoma.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has improved outcomes for patients with esophageal squamous cell carcinoma (ESCC), yet a substantial proportion develop resistance. The tumor microenvironment (TME) drives this resistance through four hallmarks: physical barriers formed by cancer-associated fibroblast (CAF)-deposited extracellular matrix (ECM) and elevated interstitial fluid pressure (IFP), enrichment of immunosuppressive cells, effector T cell exhaustion, and impaired antigen presentation. Radiotherapy, a cornerstone of ESCC treatment, has the potential to simultaneously target these barriers through multiple complementary mechanisms. Preclinical evidence suggests that high-dose or ablative radiotherapy can drive CAFs into irreversible senescence, triggering a senescence-associated secretory phenotype (SASP) that upregulates matrix metalloproteinases (MMPs) and degrades ECM. In preclinical models, IFP can be reduced through vascular normalization (low-dose) or tumor debulking (high-dose). There is also evidence, largely from experimental systems, that radiotherapy may eliminate immunosuppressive cells, ameliorate T cell exhaustion, and upregulate MHC class I and PD-L1 expression to restore immune recognition. These immunomodulatory effects appear to be dose- and fractionation-dependent; conventional fractionation often falls below the threshold required to dismantle the physical barrier-a factor that is hypothesized to contribute to, but does not fully account for, the limited success of chemo-immuno-radiotherapy trials to date. Building on this mechanistic framework, we evaluate clinical evidence for radiotherapy-immunotherapy combinations in ICI-resistant ESCC, compare the distinct roles of stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT), and propose a "barrier-exhaustion score" as a hypothetical tool to guide individualized treatment. This review provides a mechanistic rationale and clinical perspective for radiotherapy-based strategies to overcome immunotherapy resistance in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.